NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
26.72
Dollar change
-0.09
Percentage change
-0.34
%
Index- P/E- EPS (ttm)-10.43 Insider Own48.50% Shs Outstand277.93M Perf Week3.01%
Market Cap7.43B Forward P/E- EPS next Y- Insider Trans0.03% Shs Float121.38M Perf Month-
Enterprise Value- PEG- EPS next Q- Inst Own2.20% Short Float- Perf Quarter-
Income-371.20M P/S16.41 EPS this Y19.50% Inst Trans46.34% Short Ratio- Perf Half Y-
Sales452.50M P/B- EPS next Y- ROA-187.60% Short Interest- Perf YTD-4.57%
Book/sh-73.78 P/C222.35 EPS next 5Y- ROE21.00% 52W High30.70 -12.96% Perf Year-
Cash/sh0.12 P/FCF- EPS past 3/5Y- - ROIC- 52W Low25.56 4.54% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin46.70% Volatility4.33% - Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin-49.20% ATR (14)2.06 Perf 10Y-
Dividend Ex-DateSep 09, 2021 Quick Ratio0.70 Sales Y/Y TTM- Profit Margin-60.40% RSI (14)- Recom-
Dividend Gr. 3/5Y- - Current Ratio1.10 EPS Q/Q- SMA20-0.85% Beta- Target Price-
Payout0.00% Debt/Eq- Sales Q/Q49.90% SMA50-0.85% Rel Volume0.25 Prev Close26.81
Employees1769 LT Debt/Eq- Earnings- SMA200-0.85% Avg Volume3.84M Price26.72
IPOJun 18, 2025 Option/ShortYes / Yes EPS/Sales Surpr.- - Trades Volume970,986 Change-0.34%
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Spetzler David BaxleyPresidentJun 20 '25Option Exercise2.4475,000183,000558,668Jun 23 06:41 PM
Denton John RusselSee RemarksJun 20 '25Buy21.007,500157,500123,591Jun 23 06:34 PM
Brille Brian JSee RemarksJun 20 '25Buy21.0030,000630,000162,428Jun 23 06:30 PM